Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Taking Unparalleled Results to Treat the Next Epidemic

As a looming epidemic-level chronic disease, Algernon is likely on the cusp of a major product soon to be under significant demand.

Sticking with Algernon’s NASH studies, the Company announced in April that deeper tests into NP-135 revealed a meaningful reduction of liver hydroxyproline, a key secondary marker of fibrosis. Can you explain this for investors? ...Its always better if you are able to show that a compound’s impact on a disease can be measured using multiple indicators.

There hasn’t been a new treatment approved for CKD for many years and so to have discovered that we have multiple compounds that are showing such promise in our animal models is very exciting.

In addition to being potential new stand-alone treatments for CKD, the potential is that they might also be combined with the current standard of care resulting in an accretive effect.

95per-cent of new drugs fail before they reach human trials at an average cost of >$30M per compound. Because of our drug repurposing approach with known safe drugs, Algernon has over 5 compounds that could be advanced directly into phase II trials. This was achieved at a fraction of the cost compared with new drug development. Because of the well-established safety history of our compounds, the chances we will achieve a successful phase II trial has increased significantly. A successful phase II study means very significant value creation for the company.

The announcement of “first patient enrolled” is always a key milestone to work towards.

Corporate Video Link:

https://vimeo.com/337782354

https://stockhouse.com/news/newswire/2019/05/22/taking-unparalleled-results-to-treat-next-epidemic

/////AMG